New therapies are urgently required that efficiently kill AML cells, but have lower levels of toxicity, so that outcomes and the quality of life of AML patients can be improved. The researchers have developed a drug that targets an important protein in AML patients. This drug kills AML cells, including cells that are resistant to existing therapies, whilst leaving normal cells untouched. This project will examine strategies to enhance the effectiveness of this new drug, and decrease the rate of clearance from the blood. This project will identify new potential treatment options for AML, giving hope for better tretment options for to both adult and childhood forms of AML.
Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults, and accounts for ~20% of childhood leukaemias.